← AI Companies
Tempus AI operates an AI-powered precision medicine platform that aggregates multimodal clinical and molecular data to enable personalized healthcare and accelerate drug development.
- Share Price
- 80.54USD
- Market Cap
- 14.69BUSD
- Revenue
- 1.51BUSD
- Net Income
- -189.29MUSD
Financial data: Yahoo Finance, as of 11-Nov-2026
Price & Size
| Price |
80.54 USD |
| Market Cap |
14.69B USD |
| Shares Outstanding |
177.36M |
| Shares Float |
125.67M |
| 52w Low |
40.77 USD |
| 52w High |
89.09 USD |
| Avg Volume |
7.27M |
Valuation
| P/E (forward) |
-2036.4x |
| P/B |
29.30x |
| Enterprise Value |
15.49B USD |
| Book Value / Share |
2.75 USD |
| P/S |
9.73x |
| EV / Revenue |
10.26x |
| EV / EBITDA |
-77.40x |
Income
| Revenue |
1.51B USD |
| Revenue / Share |
8.40 USD |
| EBITDA |
-200.07M USD |
| Net Income |
-189.29M USD |
| EPS (trailing) |
-1.06 USD |
| EPS (forward) |
-0.04 USD |
Margins & Profitability
| Gross Margin |
64.5% |
| Operating Margin |
-13.8% |
| Profit Margin |
-12.5% |
| EBITDA Margin |
-13.3% |
| Return on Equity |
-37.5% |
| Return on Assets |
-7.4% |
Cash & Debt
| Total Cash |
637.35M USD |
| Total Debt |
1.43B USD |
| Free Cash Flow |
41.29M USD |
| Operating Cash Flow |
-108.37M USD |
| Debt / Equity |
2.86x |
| Current Ratio |
2.60x |
| Quick Ratio |
2.34x |
Analyst Consensus
| Target (Mean) |
89.56 USD |
| Target (Median) |
89.50 USD |
| Target (High) |
120.00 USD |
| Target (Low) |
70.00 USD |
| Analysts' Rating |
Buy |
| # Analysts |
18 |
Sentiment 62.0%
as of 11-Nov-2026
Sentiment is an AI (Grok) reading of market mood over the past 30 days: 0% very negative, 50% neutral, 100% very positive.
Positive drivers
Strong partnerships with major pharma firms boosted investor confidence in Tempus AI's data platform expansion. Positive analyst upgrades highlighted accelerating revenue from AI-driven oncology solutions. Growing adoption of Tempus's multimodal data analytics drove optimism around long-term growth in precision medicine.
Neutral / mixed
Mixed quarterly results reflected solid top-line growth offset by higher R&D spending. Broader market volatility in AI stocks created uncertainty without company-specific catalysts. Regulatory developments in healthcare data privacy remained ongoing without immediate impact.
Negative drivers
Increased competition from larger tech entrants pressured margins and market share expectations. Recent insider selling and lock-up expirations weighed on near-term stock performance. Macroeconomic concerns over healthcare spending cuts introduced downside risks.
Bottom line
Sentiment for TEM remains moderately positive amid AI tailwinds but tempered by competitive and spending pressures. Overall outlook leans constructive for continued platform adoption through 2026.
Nasdaq
USD